Smart monitoring solutions
to enhance cancer therapy
Winner of i-Lab 2023 innovation contest (French Minister of Higher Education and Scientific Research)
About
Beams is a medtech company incorporated since 2021 with the ambition to help surgeons better defining tumor margins.
An average of 20 to 50% of the operated patients go under local cancer recurrence. These local recurrences are mainly caused by tumor residues remaining in the operative wound after surgery.
Ensuring clear margins means ensuring the whole removal of tumor tissues, while preserving surrounding healthy tissues, not to damage functional zones.
TRIOP
Tumor Resection Intra-
Operative Probe
Beams develops TRIOP technology, a combination between a beta particles detector and a surgical aspirator.
TRIOP detects in situ previously injected commercial beta radiotracers. These radiotracers, currently used for diagnostic (PET-scans imaging) and therapy (internal radiotherapy), enable a very specific and sensitive detection. When a tumor tissue is localised, the surgeon is warned within seconds. Therefore, surgeons can make a precise distinction between healthy and tumorous tissues during their surgery and ensure clear margins.
Team
Stéphane Palfi
Medical advisor & Co-founder
Neurosurgeon
Henri Mondor; INSERM
Laurent Ménard
Scientifical advisor & Co-founder
Teacher and researcher
Université Paris Cité; IJCLab
Partners
Scientific collaborations
Public funding
Awards and prizes
Scientific collaborations
Public funding
Awards and prizes
Early support and communities
In the news
Contact us
Headquarters location
Beams
30/32 Boulevard de Sébastopol
75004 Paris
contact@beams.bio